July 30, 2016 1:09 AM ET

Capital Markets

Company Overview of Auven Therapeutics Management L.L.L.P

Company Overview

Auven Therapeutics Management L.L.L.P formerly known as Celtic Therapeutics Holdings L.P. is a private equity firm specializing in acquiring and investing in proprietary therapeutic product candidates (small-molecules and biologics), drug development, and complementary technologies. The firm also invests in developing mid-stage pharmaceutical programs. It acquires ownership of clinical-stage therapeutic assets and potential new products, primarily mid-stage development programs, with all their associated intellectual property and proprietary preclinical and clinical data. Auven Therapeutics Management L.L.L.P was founded in 2007 and is based in Saint Thomas, Virgin Islands, with additional o...

6501 Redhook Plaza

Suite 201

Saint Thomas, VI 00802

United States

Founded in 2007





Key Executives for Auven Therapeutics Management L.L.L.P

Co-Founder and Co-Managing General Partner
Age: 62
Co-Founder and Co-Managing General Partner
Age: 68
Managing Director, Chief Legal Officer, and Chief Administrative Officer
Age: 52
Partner and Managing Director of Investments and Business Development, U.S.
Age: 62
Partner of European Origination and Managing Director of Investments and Business Development, Europe
Compensation as of Fiscal Year 2016.

Auven Therapeutics Management L.L.L.P Key Developments

Auven Therapeutics Announces Initiation of Confirmatory Phase 3 Clinical Trial of Seciera (OTX-101) for the Treatment of Dry Eye Disease

Auven Therapeutics announced the first patient has been dosed in its Phase 3 confirmatory study of Seciera (OTX-101), a novel patented nanomicellar formulation of cyclosporine for the treatment of dry eye disease. Following several consultations with the U.S. Food and Drug Administration (FDA), this Phase 3 trial has been designed to confirm the significant, clinically meaningful increase in tear production (as measured by the Schirmer’s test) that was demonstrated in the previous Phase 2b/3 study. The large reduction in signs of ocular surface inflammation compared to placebo-vehicle seen in the Phase 2b/3 study will be one of several secondary endpoints in the Phase 3 study. Approximately 700 patients will be enrolled at 51 U.S. trial sites. Auven has commissioned an independent commercial assessment of Seciera including key opinion leader and third-party payor interviews. Auven believes that Seciera will be prescribed for the treatment of moderate to severe dry eye disease by a substantial portion of ophthalmologists and should achieve peak global sales in excess of $1 billion per year.

Auven Therapeutics and Bellus Health Announce Completion of Pivotal Phase 3 Confirmatory Trial of KIACTA for the Treatment of Orphan Disease AA Amyloidosis

Auven Therapeutics and BELLUS Health Inc. announced the completion of the KIACTA (eprodisate) Phase 3 confirmatory study for the treatment of AA amyloidosis. Top-line results are expected to be announced in second quarter of 2016 after all remaining patients have completed final study visits, all queries have been resolved based on input from study sites and the database has been locked.

Similar Private Companies By Industry

Company Name Region
@Visory LLC United States
1 Road Partners LLC United States
11T Partners, LLC United States
13D Research (USVI) LLC. United States
1509225 Ontario, Inc. United States

Recent Private Companies Transactions

Private Placement
September 2, 2015
ADC Therapeutics SA

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Bloomberg L.P. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Auven Therapeutics Management L.L.L.P, please visit www.auventx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.